New Catalent CEO Announces New Operating StructureBy
Catalent has announced changes to its operating structure and executive leadership team that consolidates four reporting segments to two, one focusing on biologics and the other on pharmaceuticals and consumer health. The changes went into effect July 1 (July 1, 2022) with Alessandro Maselli, formerly Catalent’s President and Chief Operating Officer, taking the helm as President and CEO, effective July 1. Catalent had announced the change in leadership in January (January 2022).
Among the leadership changes, Dr. Aris Gennadios was named Group President of Catalent’s newly formed Pharma and Consumer Health segment. The new segment consolidates the company’s prior Softgel & Oral Technologies segment, which Gennadios had led since 2013, and its Oral & Specialty Delivery and Clinical Supply Services segments.
The new Pharma and Consumer Health segment will encompass three prior segments, including the company’s softgels, Zydis fast-dissolve technologies, gummy dosage forms, clinical development and trial supply services, and global pharma manufacturing platforms.
The scope of Catalent’s other reporting segment, Biologics, continues without any change. This organizational restructuring has also been accompanied by a few additional leadership changes. Jonathan Arnold, who previously served as President, Oral & Specialty Delivery, since 2017, is Catalent’s new Senior Vice President, Chief Commercial Officer, and Head of Transformation.
Additionally, Steven Fasman, who previously served as Senior Vice President and General Counsel since 2014, will be Catalent’s Executive Vice President and Chief Administrative Officer, a newly created position. Mr. Fasman will oversee certain administrative functions of the company, including legal & compliance, information technology, engineering, procurement, governmental affairs, and various ESG-related departments.
Finally, Karen Flynn, Catalent’s Senior Vice President and Chief Commercial Officer, has announced her decision to retire.